Thromboprophylaxis in Intensive Care Unit Patients

Fachrizal Rikardi, Calcarina Fitriani R.W

Abstract

Background: Intensive Care Unit (ICU) patients are at twice the risk of experiencing thrombosis compared to patients in regular wards. This risk is associated with prolonged immobility, sedation, and neuromuscular blockade to facilitate ventilation. The incidence ranges from 8-40%. This undoubtedly leads to poorer patient outcomes, including increased patient mortality. ICU patients require prophylaxis to prevent thrombotic events. The use of thromboprophylaxis has been shown to reduce mortality rates in these patients.
Content: Intensive Care Unit (ICU) patients are at risk of developing thrombosis, which is closely related to Virchow's triad, which consists of venous stasis, endothelial dysfunction, and hypercoagulability. Considering the high morbidity associated with thrombotic events and the low side effects of carefully administered anticoagulants, pharmacological prophylaxis should be provided to all critically ill patients without contraindications to anticoagulants. Regular monitoring is necessary when administering pharmacological prophylaxis. Compared with UFH and mechanical compression, LMWH is the preferred thromboprophylaxis for ICU patients. Generally, patients weighing 50-100 kg can be given LMWH, such as enoxaparin, at a subcutaneous dose of 40 mg per day. The discontinuation of thromboprophylaxis should consider the patient's clinical condition and drug side effects.
Summary: Thromboprophylaxis is highly necessary for Intensive Care Unit (ICU) patients. The preferred thromboprophylaxis for ICU patients is LMWH. In certain circumstances, UFH or mechanical thromboprophylaxis may be considered.

Keywords

Intensive care unit; Thrombosis; Thromboprophylaxis.

Full Text:

PDF

References

Emmanuel Häfliger, MD; Basil Kopp; Pauline Darbellay Farhoumand,MD;Damien Choffat, MD; Jean-Benoît Rossel, PhD; Jean-LucReny, MD,PhD; Drahomir Aujesky, MD,MSc; Marie Méan,MD; Christine Baumgartner,MD, MAS Risk Assessment Modelsfor Venous Thromboembolism in MedicalI n patients, JAMA Network Open. 2024;7(5):e249980. doi:10.1001/jamanetworkopen.2024.9980
2. Li L, Zhen J, Huang L, Zhou J, Yao L, Xu L, et al. The risk factors for deep venous thrombosis in critically ill older adult patients: a subgroup analysis of a prospective, multicenter, observational study. BMC Geriatr. 2022;22(1).
3. Miri MM, Goharani R, Sistanizad M. Deep vein thrombosis among intensive care unit patients; An epidemiologic study. Arch Acad Emerg Med. 2019;7(1).
4. Ashish Kumar, Yatin Mehta, Tariq Ali, Mukesh Kumar Gupta, Joby V George Deep vein thrombosis in medical and surgical Intensive Care Unit patients in a Tertiary Care Centre in North India: Incidence and risk factors, Journal of Anaesthesiology Clinical Pharmacology | Volume 33 | Issue 2 | April-June 2017
5. Malato A, Dentali F, Siragusa S, Fabbiano F, Kagoma Y, Boddi M, et al. The impact of deep vein thrombosis in critically ill patients: A meta-analysis of major clinical outcomes. Vol. 13, Blood Transfusion. 2015.
6. Kaplan D, Charles Casper T, Gregory Elliott C, Men S, Pendleton RC, Kraiss LW, et al. VTE incidence and risk factors in patients with severe sepsis and septic shock. Chest. 2015;148(5).
7. Ejaz A, Ahmed MM, Tasleem A, Khan Niazi MR, Ahsraf MF, Ahmad I, et al. Thromboprophylaxis in Intensive Care Unit Patients: A Literature Review. Cureus. 2018;
8. Ovidiu Rusalim Petris, Elena Cojocaru, Ariadna Petronela Fildan, and Cristian Cojocaru, COPD and Anticoagulation Therapy: Time for a New Approach?, Int J Chron Obstruct Pulmon Dis. 2021; 16: 3429–3436. Published online 2021 Dec 18. doi: 10.2147/COPD.S340129
9. Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano CA, Lugosi M, et al. Venous thromboembolism in the ICU: Main characteristics, diagnosis and thromboprophylaxis. Vol. 19, Critical Care. 2015.
10. Li Li, Junhai Zhen, Liquan Huang, Jia Zhou, Lina Yao, Lingen Xu, Weimin Zhang, Gensheng Zhang, Qijiang Chen, Bihuan Cheng,Shijin Gong, Guolong Cai, Ronglin Jiang The risk factors for deep venous thrombosis in critically ill older adult patients: a subgroup analysis of a prospective, multicenter, observational study, Li et al. BMC Geriatrics (2022) 22:977 https://doi.org/10.1186/s12877-022-03599-y
12. Garmo C, Bajwa T, Burns B. Physiology, Clotting Mechanism. In: StatPearls, Treasure Island (FL. StatPearls Publishing; 2023. p. 1–11.
13. Zheng Y, Wu J, Zhu Y, Wu C. Inorganic-based biomaterials for rapid hemostasis and wound healing. Vol. 14, Chemical Science. 2022.
14. Boddi M, Peris A. Deep vein thrombosis in intensive care. Adv Exp Med Biol. 2017;906.
15. Lilly CM, Liu X, Badawi O, Franey CS, Zuckerman IH. Thrombosis prophylaxis and mortality risk among critically Ill adults. Chest. 2014;146(1).
16. Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. Semin Thromb Hemost. 2015;41(1).
17. NICE. Venous thromboembolism in over 16 s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE Guidance. 2018;(March).
18. Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Prophylaxis for hospitalized and nonhospitalized medical patients. Vol. 2, Blood Advances. 2018.
19. Li, Guowei MBBS, MSc; Cook, Deborah J. MD; Levine, Mitchell A.H. MD; Guyatt, Gordon MD; Crowther, Mark MD; Heels-Ansdell, Diane MSc; Holbrook, Anne MD, PharmD; Lamontagne, Francois MD; Walter, Stephen D. PhD; Ferguson, Niall D. MD; Finfer, Simon MD; Arabi, Yaseen M. MD; Bellomo, Rinaldo MD; Cooper, D. Jamie MD, PhD; Thabane, Lehana PhD Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients, Medicine 94(36):p e1479, September 2015. | DOI: 10.1097/MD.0000000000001479
20. Beitland S, Sandven I, Kjærvik LK, Sandset PM, Sunde K, Eken T. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Vol. 41, Intensive Care Medicine. 2015.
21. Julie Helms, Saskia Middeldorp and Alex C. Spyropoulos Thromboprophylaxis in critical care, Intensive Care Med (2023) 49:75–78 https://doi.org/10.1007/s00134-022-06850-7
22. Nicolaides A, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, et al. Critical Care Medical Patients. Clinical and Applied Thrombosis/Hemostasis. 2013 Apr 25;19(2):171–2.
23. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine. 2014;368(6).
24. Saketh R Guntupalli , Alyse Brennecke , Kian Behbakht, Anna Tayebnejad, Christopher A Breed, Lisa Marie Babayan , Georgina Cheng, Amin A Ramzan, Lindsay J Wheeler, Bradley R Corr, Carolyn Lefkowits , Jeanelle Sheeder, Koji Matsuo, Dina Flink ,Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm, JAMA Netw Open. 2020 Jun 26;3(6): e207410. doi:10.1001/jamanetworkopen.2020.7410
25. Ran Zhang, Weige Sun, Yana Xing, Yongjun Wang, Zixiao Li, Liping Liu, Hongqiu Gu , Kaixuan Yang, Xin Yang, Chunjuan Wang, Qingbo Liu, Qian Xiao, Weixin Cai Implementation of early prophylaxis for deep-vein thrombosis in intracerebral hemorrhage patients: an observational study from the Chinese Stroke Center Alliance, Thromb J . 2024 Feb 28;22:22. doi: 10.1186/s12959-024-00592-w
26. Lu Wang, Xudong Ma, Huaiwu He, Longxiang Su, Yanhong Guo, Guangliang Shan , Ye Wang , Xiang Zhou, Dawei Liu , Yun Long,Association Between Different DVT Prevention Methods and Outcomes of Septic Shock Caused by Intestinal Perforation in China: A Cross-Sectional Study, Front. Med., 27 April 2022 Sec. Intensive Care Medicine and Anesthesiology Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.878075
27. Waleed Alhazzani , Wendy Lim, Roman Z Jaeschke, Mohammad Hassan Murad, Jack Cade, Deborah J Cook , Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials, Crit Care Med.2013 Sep; 41(9):2224-6. doi: 10.1097/CCM.0b013e31828fd852. PMID: 23979368
28. Hui Jiang, Jia Meng, Ting Guo, Jian-ning Zhao, Yi-cun Wang, Jun Wang, Yang Qiu, and Hao Ding Comparison of Apixaban and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis after Total Knee Arthroplasty in Older Adults, Yonsei Med J 2019 Jul;60(7):626-632 https://doi.org/10.3349/ymj.2019.60.7.626
29. Robert A Fowler, Nicole Mittmann , William Geerts , Diane Heels-Ansdell , Michael K Gould , Gordon Guyatt, Murray Krahn , Simon Finfer , Ruxandra Pinto , Brian Chan, Orges Ormanidhi, Yaseen rabi , Ismael Qushmaq , Marcelo GRocha, Peter Dodek, Lauralyn McIntyre , Richard Hall , Niall D Ferguson , Sangeeta Mehta , John C Marshall , Christopher James Doig ,John Muscedere , Michael J Jacka , James R Klinger , Nicholas Vlahakis, Neil Orford , Ian Seppelt, Yoanna K Skrobik , Sachin Sud , John F Cade , Jamie Cooper , Deborah Cook ; Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients, JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101.
30. Benjamin N Jacobs , Anne H Cain-Nielsen, Jill L Jakubus , Judy N Mikhail , John J Fath , Scott E Regenbogen , Mark R Hemmila Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma, J Trauma Acute Care Surg. 2017 Jul;83(1):151–158. doi: 10.1097/TA.0000000000001494
31. Sophie Samuel, Catherine To , Yaobin Ling , Kai Zhang , Xiaoqian Jiang , Elmer V Bernstam , Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients, J Thromb Thrombolysis. 2023 Jan 10;55(3):439–448. doi: 10.1007/s11239-022-02755-w
32. Rishi Wadhera, MD; Gregory Piazza, MD, FACC , Cost-Effectiveness of LMWH vs. UFH for VTE Prophylaxis in Critically Ill Patients, Dec 16, 2014 , https://www.acc.org/Latest-in-Cardiology/Articles/2014/12/16/09/55/Cost-Effectiveness-of-LMWH-vs-UFH-for-VTE-Prophylaxis-in-Critically-Ill-Patients
33. Fernando SM, Tran A, Cheng W, Sadeghirad B, Arabi YM, Cook DJ, et al. VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. Chest. 2022;161(2).
34. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of Venous Thromboembolism. Chest. 2008 Jun;133(6):381S-453S.
35. Arabi YM, Khedr M, Dara SI, Dhar GS, Bhat SA, Tamim HM, et al. Use of intermittent pneumatic compression and not graduated compression stockings is associated with lower incident VTE in critically ill patients: A multiple propensity scores adjusted analysis. Chest. 2013;144(1).
36. Hobson DB, Chang TY, Aboagye JK, Lau BD, Shihab HM, Fisher B, et al. Prevalence of graduated compression stocking–associated pressure injuries in surgical intensive care units. J Crit Care. 2017;40.
37. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Vol. 123, Blood. 2014.
38. Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep. 2013;1(2).
39. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral Anticoagulants. Chest. 2012 Feb;141(2):e24S-e43S.
40. Hind H. Lazrak, Emilie René, Naoual Elftouh, Jean-Philippe Lafrance , Association Between Low-Molecular-Weight Heparin and Risk of Bleeding Among Hemodialysis Patients: A Retrospective Cohort Study, Canadian Journal of Kidney Health and DiseaseVolume 5, 2018 https://doi.org/10.1177/2054358118792010
41. Zullino S, Clemenza S, Mecacci F, Petraglia F. Low Molecular Weight Heparins (LMWH) and Implications along Pregnancy: a Focus on the Placenta. Vol. 29, Reproductive Sciences. 2022.
42. Peter AG Sandercock, Tze Shin Leong,Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke, Cochrane Database Syst Rev . 2017 Apr 4;2017(4):CD000119. doi: 10.1002/14651858.CD000119.pub4
43. David A Forsh, MD; Chief Editor: Vinod K Panchbhavi, MD, FACS, FAOA, FABOS, FAAOS , Deep Venous Thrombosis Prophylaxis in Orthopedic Surgery, August 2024, updated European guidelines for prophylaxis of VTE in nonambulatory orthopedic surgery, emedicine.medscape.com/article/1268573-overview
44. L Mast , M Y M Peeters , M Söhne , C M Hackeng , C A J Knibbe , M P H van den Broek , The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients, Eur J Clin Pharmacol . 2023 Sep 14;79(11):1537–1547. doi: 10.1007/s00228-023-03558-5
45. Qinan Yin, Lizhu Han, Yin Wang, Fengjiao Kang1,Fengqun Cai, Liuyun Wu, Xingyue Zheng, Lian Li, Li e Dong, Limei Dong, Shuhong Liang, Min Chen, Yong Yang and Yuan Bian, Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions, Front. Pharmacol., 11 March 2024 Sec. Cardiovascular and Smooth Muscle Pharmacology Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1352982
46. Siavash Piran1 and Sam Schulman ,Treatment of bleeding complications in patients on anticoagulant therapy, The American Society of Hematology blood® 31 January 2019 | Volume 133, Number 5
47. Rupert M. Bauersachs, MD, Fondaparinux Sodium: Recent Advances in the Management of Thrombosis, Journal of Cardiovascular Pharmacology and Therapeutics Volume 28, 2023.
48. Mohammad H. Al-Shaer, PharmD, BCPS, and Tarek Ibrahim, MClinPharm, Safety and Efficacy of Fondaparinux in Renal Impairment, Journal of Pharmacy Technology 2015, Vol. 31(4) 161 –166.
49. James D. Douketis, M.D. , Alex C. Spyropoulos, M.D. Perioperative Management of Anticoagulant and Antiplatelet Therapy, Published May 23, 2023 NEJM Evid 2023;2(6) DOI: 10.1056/EVIDra2200322 VOL. 2 NO. 6.
50. Shixuan Liu , Shuang Li , Guomin Shen, Narayanasami Sukumar, Andrzej M Krezel, Weikai Li , Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation, Science . 2020 Nov 5;371(6524) : eabc5667. doi: 10.1126/science.abc5667
51. Gianluigi Savarese MD , Robert P. Giugliano MD, SM , Giuseppe M.C. Rosano MD, PhD, John McMurray MD, Giulia Magnani MD, Gerasimos Filippatos MD,PhD, Santo Dellegrottaglie MD, PhD, Lars H. Lund MD, PhD , Bruno Trimarco MD, PhD , Pasquale Perrone-Filardi MD, PhD , Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis, JACC: Heart Failure Volume 4, Issue 11, November 2016, Pages 870-880, https://doi.org/10.1016/j.jchf.2016.07.012
52. Sharon Wei, Aanchal Sawhney, Harshwardhan Khandait, Amit Meda, Vasu Gupta, Rohit Jain, An update on applications and limitations of direct oral anticoagulants, The Egyptian Journal of Internal Medicine (2023) 35:26 https://doi.org/10.1186/s43162-023-00212-5
53. Wanwarang Wongcharoen, MD; Phongsathon Pacharasupa, MD; Lalita Norasetthada, MD; Siriluck Gunaparn; Arintaya Phrommintikul, MD Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation, Circ J 2020; 84: 1075 – 1082 doi: 10.1253/circj.CJ-20-0056
54. Helms J, Middeldorp S, Spyropoulos AC. Thromboprophylaxis in critical care. Intensive Care Med. 2023;49(1).
55. Adams CD, Anger KA, Greenwood BC, Fanikos J. Antithrombotic pharmacotherapy. In: Irwin and Rippe’s intensive care medicine. 7th ed. Philadelphia: Lippincott, Williams, and Wilkins; 2012. p. 1224–42.

DOI: https://doi.org/10.20961/soja.v4i2.93687

Refbacks

  • There are currently no refbacks.